Canada: Generic Rxs Outpacing Brands

10 March 1997

Sales and prescriptions of generic drug products through Canadian retailpharmacies grew at a faster rate than those of brand-name drugs in 1996, according to IMS Canada, which adds that the number of brand-name prescriptions dispensed last year actually declined.

In each of the past four years, generic prescription drug sales have consistently outpaced their brand-name counterparts, says IMS. During 1996, the dollar volume of generic sales to retail pharmacies increased 21.1% over 1995, compared to 1.5% growth for branded drugs. Sales growth for the entire prescription sector in 1996 was 4.4%, of which generics took 17% and brand-name products 83%. As recently as 1991, generics accounted for only 11% of the market.

Generic drug prescriptions dispensed by retail pharmacies in 1996 rose 8.9%, while brand-name prescriptions fell 0.8%. Total prescriptions rose 2.8% to 233.8 million. Generics now represent 39.8% of prescriptions, while brand-name prescriptions account for 60.2%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight